Evidence map›Paper›PMID 29916308›Full record

ArticleTechnology in cancer research & treatment2018

The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.

He Xiaoyu, Yin Yiru, Shi Shuisheng, Cheng Keyan, Yan Zixing, Cheng Shanglin, Wang Yuan, Cheng Dongming, Zhang Wangliang, Bai Xudong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Transferrin Receptor Is Necessary for Proper Oligodendrocyte Iron Homeostasis and Development.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Targeting the Microenvironment in Esophageal Cancer.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

He Xiaoyu1 Cardiothoracic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yin Yiru2 Translational Medicine Research Center, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, China.
Shi Shuisheng3 Endoscopy Center, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Cheng Keyan4 Gynecology and Obstetrics, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yan Zixing1 Cardiothoracic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Cheng Shanglin1 Cardiothoracic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wang Yuan3 Endoscopy Center, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Cheng Dongming1 Cardiothoracic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhang Wangliang5 Department of Pathology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Bai Xudong6 Cardiothoracic Surgery, Shanxi Academy of Medical Sciences, Shanxi Dayi Hospital, China.
Ma Jie1 Cardiothoracic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Second Hospital of Shanxi Medical University · CNShanxi Medical University · CNShanxi Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEsophageal squamous cell carcinoma is a highly prevalent cancer withpoor survival rate and prognosis. Increasing evidence suggests an important role for metabolic regulation in treating esophageal squamous cell carcinoma, but the underlying mechanism remains unclear. The pyruvate kinase M2 isoform is a key enzyme in the energy production process, and the upregulation of pyruvate kinase M2 isoform also plays a crucial role in gene transcription and tumorigenesis. The mammalian target of rapamycin pathway regulates an array of cellular functions, including protein synthesis, metabolism, and cell proliferation. The pyruvate kinase M2 isoform and mammalian target of rapamycin pathways both affect metabolism in cancers, and evidence also suggests that the mammalian target of rapamycin downstream transcription factor hypoxia-inducible factor-1α regulates pyruvate kinase M2 isoform. We therefore investigated the regulatory mechanism among pyruvate kinase M2 isoform, mammalian target of rapamycin, and aerobic glycolysis in esophageal squamous cell carcinoma, hoping to prove that mammalian target of rapamycin pathway regulates pyruvate kinase M2 isoform to affect glycolysis in esophageal squamous cell carcinoma.

methodsImmunohistochemical staining was used to compare pyruvate kinase M2 isoform and phospho-mammalian target of rapamycin expression in 30 human pathological esophageal squamous cell carcinoma sections and 30 nontumoral esophageal tissues. Short hairpin RNA was used to inhibit pyruvate kinase M2 isoform and activate mammalian target of rapamycin, after which we monitored changes in glucose consumption and lactate production. Finally, we determined the expression of pyruvate kinase M2 isoform and the mammalian target of rapamycin downstream transcription factor hypoxia-inducible factor-1α, as well as glucose consumption and lactate production, following the modification of mammalian target of rapamycin expression.

resultsImmunohistochemical staining showed that both phospho-mammalian target of rapamycin and pyruvate kinase M2 isoform expression were higher in esophageal squamous cell carcinoma than in nontumor tissues. Glucose consumption and lactate production measurements demonstrated that altering mammalian target of rapamycin and pyruvate kinase M2 isoform levels caused corresponding changes in glycolysis in esophageal squamous cell carcinoma cells. When mammalian target of rapamycin was activated or inhibited, expression of pyruvate kinase M2 isoform and hypoxia-inducible factor-1α as well as glycolysis were altered, indicating that mammalian target of rapamycin regulates pyruvate kinase M2 isoform via the downstream transcription factor hypoxia-inducible factor-1α, thereby affecting glycolysis in esophageal squamous cell carcinoma.

conclusionMammalian target of rapamycin pathway promotes aerobic glycolysis in esophageal squamous cell carcinoma by upregulating pyruvate kinase M2 isoform. Both proteins can serve as molecular targets for novel therapeutic strategies.

Indexed as

Carrier ProteinsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGlycolysisHumansMaleMembrane ProteinsSignal TransductionThyroid Hormone-Binding ProteinsThyroid HormonesTOR Serine-Threonine KinasesCarrier ProteinsMembrane ProteinsMTOR protein, humanThyroid Hormone-Binding ProteinsThyroid HormonesTOR Serine-Threonine KinasesESCCglycolysismTORPKM2PTEN

Identifiers

PMID29916308
PMCPMC6024499
OpenAlexW2808734338

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.